As­traZeneca, Mer­ck notch an­oth­er ma­jor Lyn­parza tri­al win — this time in pan­cre­at­ic can­cer

As­traZeneca and Mer­ck’s PARP in­hibitor Lyn­parza has chalked up an­oth­er land­mark win.

Months af­ter se­cur­ing a light­ning fast ap­proval for the use of the drug in front­line ovar­i­an can­cer — widen­ing their lead over the clus­ter of oth­er PARPs in­clud­ing Tesaro’s (now GSK’s) Ze­ju­la and Clo­vis’ Rubra­ca — Lyn­parza has shown promise in help­ing pa­tients with BR­CA-mu­tat­ed metasta­t­ic pan­cre­at­ic can­cer live longer with­out their can­cer pro­gress­ing in a late-stage study.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN